Ubiquitin-specific protease 22 promotes the proliferation, migration and invasion of glioma cells
Male
Carcinogenesis
Apoptosis
Glioma
3. Good health
Gene Expression Regulation, Neoplastic
03 medical and health sciences
0302 clinical medicine
Cell Movement
Cell Line, Tumor
Gene Knockdown Techniques
Biomarkers, Tumor
Humans
Matrix Metalloproteinase 2
Female
Neoplasm Invasiveness
Thiolester Hydrolases
Ubiquitin Thiolesterase
Cell Proliferation
Signal Transduction
DOI:
10.3233/cbm-181413
Publication Date:
2018-09-11T21:27:22Z
AUTHORS (6)
ABSTRACT
Ubiquitin-specific protease 22 (USP22), as one of the 11 death-from-cancer signature genes, presented high expression in a variety of tumors. Previous studies showed that USP22 played a significant role in cell-cycle, oncogenesis, clinicopathology and survival. Our studies have presented USP22 was over-expressed in glioma tissue and the patients with high expression of USP22 had a poor survival than that with low expression of USP22. However, the concrete effect of USP22 on biological behavior in glioma cells has been rarely reported. The study aimed to clear the effect of USP22 on cell proliferation, migration and invasion in glioma. Using siRNA, USP22 was knocked down in U251 and U87 glioma cells and successful transfection effect was validated. Cell proliferation, migration and invasion were observed by the methods of EdU, Wound healing and Transwell assay, separately. At the same time, the expression of MMP2 was detected by Gelatin zymography after transfecting siRNAs. After the knockdown of USP22 by siRNA, the abilities of glioma cell proliferation, migration and invasion were decreased, accompanying, the expression of MMP2 was also decreased. We drew a conclusion that USP22 could increase the abilities of proliferation, migration and invasion of glioma cells, and promote the growth and development of glioma.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (25)
CITATIONS (11)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....